A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

Abstract

Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of ! 700 days from the initiation of sitagliptin treatment and the measurement of hemoglobin A1c (HbA1c) had been performed at 0, 3, 6, 12, 18, and 24 months after the initiation of treatment. From the population of 616 patients, 447 and 169 had received sitagliptin for ! 700 and <700 days, respectively. The primary endpoint was ΔHbA1c at 24 months. The factors associated with the hypoglycemic effect of sitagliptin were also investigated. Results Sitagliptin treatment significantly decreased the level of HbA1c, and the hypoglycemic effect was sustained for at least 2 years. The baseline HbA1c level, duration of diabetes, Δbody weight value, and ΔHbA1c value at 3 months were independently associated with the hypoglycemic effect of sitagliptin. Conclusion Sitagliptin has a long-term hypoglycemic effect in type 2 diabetes patients. A patient's ΔHbA1c at 3 months may be a predictor of their ΔHbA1c at 24 months.

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

“…Although, if study drug doesn’t work enough, to fix medication for a long time is not good for patients. On the other hand, Nishimura et al reported that a patient’s HbA1c change at 3 months may be a predictor of their HbA1c change at 24 months [11]. And our study also showed the HbA1c level of 12 month was similar to 3 month.…”

“…In many studies, sitagliptin reportedly improved HbA1c and fasting blood glucose levels both as a single-drug therapy [3, 8–10] and as a combination therapy with other antidiabetic drugs [4, 5, 11]. In our study, we excluded patients undergoing insulin use, also some clinical trials [12, 13] reported about the combination therapy about sitagliptin and insulin.…”

Accurate and Rapid Measurement of Glycated Hemoglobin Using HLC-723 G11 Variant Mode

“…Diabetes mellitus is diagnosed based on symptoms, fasting plasma glucose concentration, oral glucose tolerance test, and glycated Hb (HbA1c) measurement. Among these, HbA1c reflects blood glucose status over the three prior months and is widely used because it plays an important role in predicting the prognosis of the therapeutic effect as well as in diagnosis and follow-up [34]. As HbA1c test results have become more important and the demand for the test has increased, fast and accurate reporting of HbA1c test results has become one of the main challenges.…”